Nanosuspensions of a poorly soluble investigational molecule ODM-106: Impact of milling bead diameter and stabilizer concentration.

Hydrophobic drug Nanocrystals Nanonization Stabilizer Surfactant Wet milling

Journal

International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127

Informations de publication

Date de publication:
25 Sep 2020
Historique:
received: 30 04 2020
revised: 06 07 2020
accepted: 07 07 2020
pubmed: 14 7 2020
medline: 22 6 2021
entrez: 14 7 2020
Statut: ppublish

Résumé

Aqueous solubility of a drug substance is an important attribute affecting oral bioavailability. Nanonization, particle size reduction to submicron level, is an elegant approach to improve drug solubility and dissolution by increasing the surface energy, which in turn necessitates the use of stabilizers. The purpose of this study was to develop a nanosuspension of a practically water-insoluble investigational molecule by nanomilling approach using wet media milling. A variety of polymeric and surface active excipients were tested for their wettability. A combination of hydroxypropyl methylcellulose and sodium lauryl sulfate (SLS) were selected as stabilizers on the bases of compatibility studies and efficient wettability behaviour in contact angle measurements (≈80˚). A factorial design set-up was used to study the effect of milling bead diameter and stabilizer concentration on the efficiency of particle size reduction. Nanonization outcome was different when milling beads of 0.5 mm and 1 mm diameter were used at different concentrations of the stabilizers, which demonstrated the complex nature of the whole system. Storage of the nanosuspensions under different temperature conditions resulted only in minor changes of the particle size fractions.

Identifiants

pubmed: 32659405
pii: S0378-5173(20)30620-7
doi: 10.1016/j.ijpharm.2020.119636
pii:
doi:

Substances chimiques

Excipients 0
Suspensions 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

119636

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Mayank Singhal (M)

Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, Viikinkaari 5 E, 00014 Helsinki, Finland; Orion Pharma R&D, Global Pharmaceutical Research, P.O. Box 65, 02101 Espoo, Finland.

Ana Baumgartner (A)

Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, Viikinkaari 5 E, 00014 Helsinki, Finland.

Elina Turunen (E)

Orion Pharma R&D, Global Pharmaceutical Research, P.O. Box 65, 02101 Espoo, Finland.

Bert van Veen (B)

Orion Pharma R&D, Global Pharmaceutical Research, P.O. Box 65, 02101 Espoo, Finland.

Jouni Hirvonen (J)

Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, Viikinkaari 5 E, 00014 Helsinki, Finland.

Leena Peltonen (L)

Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, Viikinkaari 5 E, 00014 Helsinki, Finland. Electronic address: leena.peltonen@helsinki.fi.

Articles similaires

Tumor Microenvironment Nanoparticles Immunotherapy Cellular Senescence Animals
Cobalt Azo Compounds Ferric Compounds Polyesters Photolysis
Neoplastic Stem Cells Animals Humans Aldehyde Dehydrogenase Tretinoin
NLR Family, Pyrin Domain-Containing 3 Protein Autophagy Inflammasomes Interleukin-1beta Animals

Classifications MeSH